查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1968562

多核苷酸注射市場－全球產業規模、佔有率、趨勢、機會、預測：按應用、最終用途、地區和競爭格局分類，2021-2031年

Polynucleotides Injectable Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球多核苷酸注射劑市場預計將從 2025 年的 1.3612 億美元成長到 2031 年的 2.3736 億美元，複合年成長率為 9.71%。

該市場以生物促效劑產品為特徵，這些產品通常含有源自鮭魚或鱒魚的超高純度DNA片段。注射這些產品可活化纖維母細胞，促進生理性組織再生、保濕和膠原蛋白生成，而無需人為增加皮膚容量。推動這一市場成長的主要動力是消費者偏好的顯著轉變，他們開始追求再生美容和自然美觀的效果。與傳統填充劑帶來的即時容量提升相比，患者越來越重視改善膚質和修復細胞。

市場概覽
預測期 2027-2031
市場規模：2025年 1.3612億美元
市場規模：2031年 2.3736億美元
複合年成長率：2026-2031年 9.71%
成長最快的細分市場 眼科
最大的市場 北美洲

然而，由於法規環境分散，市場面臨許多挑戰。從醫療設備到藥品，不同司法管轄區之間缺乏統一的產品分類，阻礙了全球標準化和核准。儘管存在這些監管挑戰，專業人士對該技術的接受度仍然很高。根據韓國美容整形外科學會和韓國雷射醫學會的調查，2024年接受調查的整形外科醫生中，75.7%的人表示使用多核苷酸注射治療因皮脂分泌過多引起的毛孔粗大，這表明此類治療方法在臨床實踐中正在迅速普及。

市場促進因素

市場擴張的主要驅動力是全球對微創抗衰老治療日益成長的需求。患者越來越傾向於選擇能夠改善皮膚結構、帶來自然效果且恢復期短的治療方案，而非傳統填充劑帶來的即時豐盈效果。非侵入性治療數量的激增也印證了這項轉變。根據國際美容整形外科學會 (ISAPS) 於 2024 年 6 月發布的《全球美容整形外科手術調查報告》，2023 年全球共進行了 1,910 萬例非手術治療，顯示針刺治療方法的需求持續旺盛。多核苷酸正是順應了這個趨勢，透過促進生理修復過程，從內而外增強皮膚彈性和水潤度，滿足了消費者對再生醫學解決方案的需求。

同時，多核苷酸注射劑在生髮和脫髮症治療領域的應用不斷拓展，也擴大了其潛在市場。這些注射因能促進微循環和刺激毛囊細胞增殖，有效治療男性型脫髮症（雄性脫毛症）而廣受歡迎。臨床數據也支持其療效；2024年發表於《皮膚病學研究檔案》（Archives of Dermatological Research）的一項研究報告稱，接受多核苷酸注射的患者中，77.8%在18週後出現輕度至中度的毛髮再生。該治療方法的廣泛應用也促使更多醫療專業人員採用；2024年發表於《美容皮膚病學雜誌》（Journal of Cosmetic Dermatology）的一項調查顯示，韓國88%的註冊皮膚科醫生已將多核苷酸注射納入其臨床實踐。

市場挑戰

全球多核苷酸注射劑市場面臨的主要障礙是監管環境的碎片化。這為製造商設置了複雜且成本高昂的進入門檻。由於不同地區的藥品分類不一致（多核苷酸在某些地區被歸類為醫療設備，而在其他地區則被歸類為藥品），企業必須應對不同的核准流程。這種缺乏協調性導致企業需要在每個司法管轄區分別開展耗資巨大的臨床試驗和製定合規策略，從而顯著延遲產品上市，並限制了這些注射劑的全球供應。

這種監管瓶頸直接阻礙了市場擴張，因為它無法滿足專業人士對再生美容醫學日益成長的需求。例如，美國臉部整形與重組外科學會（AAFPRS）在2024年報告稱，57%的臉部整形外科醫師認為再生醫學是一個重要的創新領域。儘管有明確證據表明市場已經成熟，且醫療專業人士的需求旺盛，但監管摩擦限制了這些專業人士可獲得的已通過核准的多核苷酸產品，人為地限制了市場潛力，並阻礙了其像在其他更標準化的美容領域那樣得到廣泛應用。

市場趨勢

年輕一代對「預防性抗衰老」策略的興起，正迅速改變全球多核苷酸注射市場的患者獲取模式。年輕消費者，尤其是千禧世代和Z世代，擴大使用這些生物促效劑，並非為了修復肌膚問題，而是作為預防措施，以維持肌膚品質並延緩老化跡象。他們被多核苷酸的特性所吸引，這些特性能夠改善肌膚水潤度和質地，而不會像傳統填充劑那樣造成結構性改變，符合所謂「玻璃肌」的美學理想。這種興趣的激增是可以量化的；根據DermaFocus在2024年12月進行的一項調查，與上個月相比，多核苷酸的網路搜尋激增了2446%。這主要是由於患者尋求名人推薦的護膚方案以達到預防老化的目的。

第二個顯著的趨勢是，多核苷酸注射療法在男性美容和護理領域的應用日益廣泛，這也擴大了該療法的治療範圍。男性患者選擇多核苷酸注射療法，因為它能夠活化肌膚，提升彈性，且不會像人工填充那樣導致臉部特徵女性化。這符合男性追求「隱藏式治療」的偏好，他們希望在解決痤瘡疤痕、偏好粗糙等特定問題的同時，保持男性化的骨骼結構。專業的臨床數據也支持這項轉變。英國美容醫學會 (BCAM) 於 2024 年 9 月發布的《BCAM 2024 年度臨床回顧》顯示，其會員醫生治療的所有患者中，男性佔 16%，這表明這些生物再生通訊協定正逐漸成為男性日常美容護理的一部分。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球多核苷酸注射劑市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依應用部位（眼部、唇部、額頭、下顎線/顴骨等）
    • 依最終用途（醫療水療中心、美容/整形中心、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美多核苷酸注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲多核苷酸注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區多核苷酸注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲多核苷酸注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲多核苷酸注射劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球多核苷酸注射劑市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • PharmaResearch
  • Bioplus Co., Ltd.
  • AMEELA
  • Mastelli Srl
  • MD Skin Solutions
  • Fox Pharma Ltd
  • BRPHARM Co., Ltd.
  • DermaFocus Ltd
  • ADM Skin Clinic
  • The Doctor & Company

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27472

The Global Polynucleotides Injectable Market is projected to expand from USD 136.12 Million in 2025 to USD 237.36 Million by 2031, reflecting a CAGR of 9.71%. This market is characterized by biostimulatory products comprising ultra-pure DNA fractions, usually sourced from salmon or trout, which are injected to stimulate fibroblasts and encourage physiological tissue regeneration, hydration, and collagen production without adding artificial volume. The primary force driving this growth is a significant shift in consumer preference toward regenerative aesthetics and natural-looking outcomes, as patients increasingly value skin quality enhancement and cellular repair over the immediate volume correction associated with traditional fillers.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 136.12 MIllion
Market Size 2031USD 237.36 MIllion
CAGR 2026-20319.71%
Fastest Growing SegmentEyes
Largest MarketNorth America

However, the market faces a substantial obstacle due to a fragmented regulatory environment, where inconsistent product classifications-ranging from medical devices to pharmaceuticals across various jurisdictions-create hurdles for global standardization and approval. Despite these regulatory challenges, professional adoption remains robust; according to the Korean Aesthetic Surgery and Laser Society, 75.7% of cosmetic physicians surveyed in 2024 reported using polynucleotide injections to treat enlarged facial pores resulting from excessive sebum production, highlighting the rapid uptake of these therapies in clinical practice.

Market Driver

The expansion of the market is largely fueled by surging global demand for minimally invasive anti-aging procedures, with patients increasingly prioritizing treatments that offer structural improvements and natural results with minimal downtime, rather than the immediate volume enhancement of traditional fillers. This shift is highlighted by the sheer volume of non-invasive treatments; the International Society of Aesthetic Plastic Surgery reported in its June 2024 'Global Survey on Aesthetic/Cosmetic Procedures' that 19.1 million non-surgical procedures were conducted worldwide in 2023, indicating a persistent appetite for needle-based therapies. Polynucleotides leverage this trend by triggering physiological repair processes that enhance skin elasticity and hydration from within, satisfying the consumer desire for regenerative solutions.

Simultaneously, the market's addressable scope is widening through growing applications in hair restoration and alopecia treatment. These injectables are gaining popularity for androgenetic alopecia by boosting microcirculation and stimulating follicle cell proliferation. Clinical data supports this efficacy; a study published in the Archives of Dermatological Research in 2024 noted that 77.8% of patients treated with polynucleotide injections experienced slight to moderate hair regrowth after 18 weeks. This therapeutic versatility has driven high adoption rates among practitioners, with a survey in the Journal of Cosmetic Dermatology in April 2024 revealing that 88% of board-certified dermatologists in South Korea have incorporated polynucleotide injections into their practice.

Market Challenge

A major factor hindering the Global Polynucleotides Injectable Market is the fragmented regulatory landscape, which imposes complex and costly barriers to entry for manufacturers. Because product classifications are inconsistent-with polynucleotides categorized as medical devices in some regions and pharmaceuticals in others-companies must navigate divergent approval pathways. This lack of harmonization requires the execution of separate, capital-intensive clinical trials and compliance strategies for each jurisdiction, significantly delaying product launches and restricting the global availability of these injectables.

This regulatory bottleneck directly stifles market expansion by preventing supply from meeting the rapidly rising professional interest in regenerative aesthetics. For instance, the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) reported in 2024 that 57% of facial plastic surgeons consider regenerative medicine a major area of innovation. Despite this clear evidence of market readiness and high practitioner demand, regulatory friction limits the number of approved polynucleotide products available to these professionals, artificially capping the market's potential and preventing these therapies from achieving the widespread adoption rates seen in more standardized aesthetic categories.

Market Trends

The rise of pre-juvenation strategies among younger demographics is rapidly shifting patient acquisition patterns within the Global Polynucleotides Injectable Market. Younger consumers, specifically Millennials and Gen Z, are increasingly using these biostimulators as a preventative measure to maintain skin quality and delay aging signs rather than for correction. This demographic is attracted to the ability of polynucleotides to improve hydration and texture without the structural changes associated with traditional fillers, aligning with the "glass skin" aesthetic. This surge in interest is quantifiable; according to DermaFocus in December 2024, internet searches for polynucleotides increased by a dramatic 2,446% over the preceding months, driven largely by patients seeking these preventative, celebrity-endorsed skin regimens.

A second pivotal trend expanding the therapy's scope is its increasing utilization in male grooming and aesthetic regimens. Male patients are gravitating toward polynucleotide injections because they offer skin revitalization and improved elasticity without adding artificial volume, which can inadvertently feminize facial features. This aligns with the male preference for undetectable treatments that maintain masculine structural definition while addressing specific issues like acne scarring or coarse texture. Professional clinical data supports this shift; the British College of Aesthetic Medicine's September 2024 'BCAM 2024 Annual Clinical Review' noted that 16% of all patients treated by member physicians were male, indicating the sustained integration of these bio-regenerative protocols into men's aesthetic maintenance routines.

Key Market Players

  • PharmaResearch
  • Bioplus Co., Ltd.
  • AMEELA
  • Mastelli Srl
  • MD Skin Solutions
  • Fox Pharma Ltd
  • BRPHARM Co., Ltd.
  • DermaFocus Ltd
  • ADM Skin Clinic
  • The Doctor & Company

Report Scope

In this report, the Global Polynucleotides Injectable Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Polynucleotides Injectable Market, By Application

  • Eyes
  • Lips
  • Forehead
  • Jawline & Cheekbones
  • Others

Polynucleotides Injectable Market, By End Use

  • Med Spas
  • Aesthetic & Cosmetic Centers
  • Others

Polynucleotides Injectable Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Polynucleotides Injectable Market.

Available Customizations:

Global Polynucleotides Injectable Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Polynucleotides Injectable Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Eyes, Lips, Forehead, Jawline & Cheekbones, Others)
    • 5.2.2. By End Use (Med Spas, Aesthetic & Cosmetic Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Polynucleotides Injectable Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Polynucleotides Injectable Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Polynucleotides Injectable Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Polynucleotides Injectable Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By End Use

7. Europe Polynucleotides Injectable Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Polynucleotides Injectable Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Polynucleotides Injectable Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Polynucleotides Injectable Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Polynucleotides Injectable Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Polynucleotides Injectable Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By End Use

8. Asia Pacific Polynucleotides Injectable Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Polynucleotides Injectable Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Polynucleotides Injectable Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Polynucleotides Injectable Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Polynucleotides Injectable Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Polynucleotides Injectable Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Polynucleotides Injectable Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Polynucleotides Injectable Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Polynucleotides Injectable Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Polynucleotides Injectable Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By End Use

10. South America Polynucleotides Injectable Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Polynucleotides Injectable Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Polynucleotides Injectable Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Polynucleotides Injectable Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Polynucleotides Injectable Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. PharmaResearch
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bioplus Co., Ltd.
  • 15.3. AMEELA
  • 15.4. Mastelli Srl
  • 15.5. MD Skin Solutions
  • 15.6. Fox Pharma Ltd
  • 15.7. BRPHARM Co., Ltd.
  • 15.8. DermaFocus Ltd
  • 15.9. ADM Skin Clinic
  • 15.10. The Doctor & Company

16. Strategic Recommendations

17. About Us & Disclaimer